This product has not been evaluated by SAHPRA. For information purposes only — not intended to diagnose, treat, cure or prevent any disease.
Weight LossResearch vialGLP-1GIPGlucagonWeight lossTriple agonist
Retatrutide
Triple GLP-1/GIP/glucagon agonist — adds thermogenic burn on top of appetite control. 50mg upgrade available.
R 1 950
30mg / 50mg vial
Triple receptorHits GLP-1, GIP, and glucagon receptors in one molecule.
-24.2% at 12 mgPhase 2 produced 24.2% mean weight loss at 48 weeks on the 12 mg arm.
Thermogenic componentGlucagon arm raises basal energy expenditure on top of appetite suppression.
Curve still climbingDose-response had not plateaued at 48 weeks — longer cycles may produce more loss.
Retatrutide (LY3437943) is a synthetic triple agonist of the GLP-1, GIP, and glucagon receptors. The GLP-1 and GIP arms work like tirzepatide; the glucagon arm adds a hepatic and thermogenic component, raising basal energy expenditure. Administered subcutaneously once weekly. Investigational — Eli Lilly is currently running phase 3 trials (TRIUMPH program).
More in Weight Loss
You might also like
Weight LossR 195
90 capsules
Natural Fat Burner
A daily botanical + thermogenic capsule designed to support metabolism and an active routine — from the Slender Living line.
View details →
Weight LossR 669
30 capsules
S30 Extreme Fat Burner
An extreme thermogenic fat-burner capsule — formulated for serious weight-loss routines and hard-training days.
View details →
Weight LossR 689
30 capsules
V30 Hardcore Fat Burner
A hardcore fat-burner capsule for advanced users — intense thermogenic support to push past plateaus.
View details →
Regulatory
This product has not been evaluated by the South African Health Products Regulatory Authority (SAHPRA).
For information purposes only — not intended to diagnose, treat, cure or prevent any disease.